Cholesterol lowering in 2015: Still answering questions about how and in whom

JAMA - Journal of the American Medical Association

Volumn 314, Issue 2, 2015, Pages 127-128

  Greenland, Philip ^a,b   Lauer, Michael S ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JAMA   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; COST EFFECTIVENESS ANALYSIS; DRUG USE; FRAMINGHAM RISK SCORE; HIGH RISK POPULATION; HUMAN; LOW RISK POPULATION; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK REDUCTION; SHORT SURVEY; UNITED STATES; ATHEROSCLEROSIS; CALCINOSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ECONOMICS; FEMALE; HYPERCHOLESTEROLEMIA; MALE;

ATHEROSCLEROSIS; CALCINOSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS;

EID: 84937413953     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.7434     Document Type: Short Survey

References (12)

1. Levy RI. Cholesterol and cardiovascular disease: no longer whether, but rather when, in whom, and how? Circulation. 1985;72(4):686-691.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
3. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
4. Psaty BM,Weiss NS. 2013 ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA. 2014;311(5): 461-462.
5. KavousiM, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416-1423.
6. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014; 311(14):1406-1415.
7. Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297(12):1376-1378.
8. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ (Clin Res Ed). 1981;282 (6279):1847-1851.
9. CooneyMT, Dudina A, Whincup P, et al. Reevaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16 (5):541-549.
10. Ioannidis JP. More than a billion people taking statins? potential implications of the new cardiovascular guidelines. JAMA. 2014;311(5):463-464.
11. Pursnani A, Massaro JM, D'Agostino RB Sr, O'Donnell CJ, Hoffmann U. Guideline-based statin eligibility, coronary artery calcification, and cardiovascular events. JAMA. doi:10.1001/jama.2015.7515.
12. Pandya A, Sy S, Cho S,Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. doi:10.1001/jama.2015.6822.